Propranolol in treating various symptoms associated with autism spectrum disorder (ASD)
DOI:
https://doi.org/10.12775/QS.2024.19.53778Keywords
autism, propranolol, beta-blockers, anxietyAbstract
Introduction and purpose
This review provides an in-depth exploration of the pharmacology of propranolol, elucidating its mechanisms of action and clinical implications beyond its conventional indications, contextualizing propranolol’s role in ASD management.
State of knowledge
Propranolol is a non-cardioselective β-adrenergic receptor antagonist, commonly used among the population. Propranolol's mechanisms include reducing cardiac workload, vasoconstriction, and membrane stabilizing properties, which suggest its utility in managing anxiety. ASD, characterized by deficits in social interaction, communication, and repetitive behaviors, affects approximately 1 in 100 children globally. Symptoms often co-occur with anxiety and hyperarousal, linked to noradrenergic system alterations.
Review methods
Electronic searches were conducted between 6 and 13 May 2024 and included databases: Pubmed and Google Scholar. This review focuses on 4 trials that are limited to years 2016-2024.
Conclusions
Overall, propranolol shows promise in managing anxiety, enhancing social communication, improving cognitive performance, and addressing severe behavioral challenges in ASD. However, variability in response highlights the need for personalized treatment approaches. Further research is warranted to optimize dosing strategies and understand propranolol's mechanisms, contributing to more effective and tailored treatment options for ASD.
References
Al-Majed, A. A., Bakheit, A. H. H., Abdel Aziz, H. A., Alajmi, F. M., & AlRabiah, H. (2017). Propranolol. Profiles of Drug Substances, Excipients and Related Methodology, 287–338. doi:10.1016/bs.podrm.2017.02.006
Mahsa S, Vikas G. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 May 1.
Wang DW, Mistry AM, Kahlig KM, Kearney JA, Xiang J, George AL (2010). "Propranolol blocks cardiac and neuronal voltage-gated sodium channels". Frontiers in Pharmacology. 1: 144. doi:10.3389/fphar.2010.00144
Sagar-Ouriaghli I, Lievesley K, & Santosh P. J, (2018). Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders. Journal of Psychopharmacology, 32(6), 641–653. doi:10.1177/0269881118756245
Levy S. E, Mandell D. S, & Schultz R. T, (2009). Autism. The Lancet, 374(9701), 1627–1638. doi:10.1016/s0140-6736(09)61376-3
Zeidan J, Fombonne E, Scorah J eta al. (2022). Global prevalence of autism: A systematic review update. Autism Res. 15(5):778-790. doi: 10.1002/aur.2696
Johnson C. P, & Myers S. M, (2007). Identification and Evaluation of Children With Autism Spectrum Disorders. PEDIATRICS, 120(5), 1183–1215. doi:10.1542/peds.2007-2361
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.), p. 154-155
Beversdorf, D. Q. (2020). The role of the noradrenergic system in autism spectrum disorders, implications for treatment. Seminars in Pediatric Neurology, 100834. doi:10.1016/j.spen.2020.100834
Lake CR, Ziegler MG, Murphy DL. Increased norepinephrine levels and decreased dopamine-beta-hydroxylase activity in primary autism. Arch Gen Psychiatry 34:553–556; 1977.
Barthelemy C, Bruneau N, Cottet-Eymard JM, Domenech-Jouve J, Garreau B, Lelord G, Muh JP, Peyrin L. Urinary free and conjugated catecholamines and metabolites in autistic children.
Ward F, Tharian P, Roy M, Deb S, & Unwin G. L, (2013). Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: A systematic review. Research in Developmental Disabilities, 34(12), 4293–4303. doi:10.1016/j.ridd.2013.08.015
Faigel HC (1991) The effect of beta blockade on stress-induced cognitive dysfunction in adolescents. Clin Pediatr 30:441–445
Lader M (1988) β-adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 49:213–223
Sagar-Ouriaghli I, Lievesley K, & Santosh P. J, (2018). Propranolol for treating emotional, behavioural, autonomic dysregulation in children and adolescents with autism spectrum disorders. Journal of Psychopharmacology, 32(6), 641–653. doi:10.1177/0269881118756245
U.S. Food and Drug Administration. (2011). Propranolol Hydrochloride Tablets https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/016418s080,016762s017,017683s008lbl.pdf
Zamzow R. M, Ferguson B. J, Stichter J. P, Porges E. C, Ragsdale A. S, Lewis M. L, & Beversdorf D. Q (2016). Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study. Psychopharmacology, 233(7), 1171–1178. doi:10.1007/s00213-015-4199-0
Hegarty J. P, Zamzow R. M, Ferguson B. J, Christ S. E, Porges E. C, Johnson J. D, & Beversdorf D. Q. (2019). Beta-adrenergic antagonism alters functional connectivity during associative processing in a preliminary study of individuals with and without autism. Autism, 136236131986863. doi:10.1177/1362361319868633
David B, Bradley F, Samantha H, et al. (2024) Randomized controlled trial of propranolol on social communication and anxiety in children and young adults with autism spectrum disorder. Psychopharmacology; 241(1):19-32. doi: 10.1007/s00213-023-06452-1.
London E. B, Yoo J. H, Fethke E. D, & Zimmerman-Bier B, (2020). The Safety and Effectiveness of High-Dose Propranolol as a Treatment for Challenging Behaviors in Individuals With Autism Spectrum Disorders. Journal of Clinical Psychopharmacology, 40(2), 122–129. DOI: 10.1097/JCP.0000000000001175
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Magdalena Gajkiewicz, Radosław Zaucha, Julia Silldorff, Tomasz Fura, Małgorzata Zając, Marcin Dudek, Zuzanna Felińska, Oliwia Iszczuk, Stanisław Anczyk

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 91
Number of citations: 0